Barclays PLC Sells 64,307 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Barclays PLC decreased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 633,125 shares of the company's stock after selling 64,307 shares during the period. Barclays PLC owned 0.16% of Recursion Pharmaceuticals worth $4,281,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Decker Retirement Planning Inc. bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $26,000. Private Trust Co. NA bought a new stake in Recursion Pharmaceuticals in the 4th quarter valued at $27,000. GAMMA Investing LLC lifted its stake in Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after purchasing an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Recursion Pharmaceuticals by 220.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock valued at $66,000 after purchasing an additional 6,758 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Trading Down 2.3 %

RXRX stock traded down $0.13 during trading on Wednesday, hitting $5.59. The company had a trading volume of 14,856,182 shares, compared to its average volume of 12,324,126. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The company has a 50 day simple moving average of $6.02 and a 200-day simple moving average of $6.77. The firm has a market capitalization of $2.25 billion, a P/E ratio of -3.65 and a beta of 1.00. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's revenue was down 57.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.42) EPS. As a group, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RXRX has been the subject of a number of research reports. KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Morgan Stanley cut their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $8.20.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.